Controlled-Release Antidiabetic Composition With Dual-Layer Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for combination therapy in Type 2 diabetes do not optimize the pharmaceutical kinetics and dynamics profiles of different antidiabetic agents, leading to suboptimal synergistic effects and potential adverse drug interactions.
Innovation Solution
A controlled release oral dosage form comprising a core portion with metformin or its salt and an outer portion with a DPP-4 inhibitor, encapsulated by a controlled membrane film with passageways for controlled release in the gastrointestinal tract, optimizing the release profiles of both agents for synergistic antidiabetic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple antidiabetic agents are administered as separate therapies, then each agent can be optimized for its individual pharmacokinetic profile, but the treatment complexity increases and synergistic effects are not optimized
Solution Approach 1:
The patent combines multiple antidiabetic agents (metformin and DPP-4 inhibitor) into a single pharmaceutical composition with distinct release profiles. The controlled-release metformin core is coated with an immediate-release DPP-4 inhibitor layer, allowing both agents to be administered together in one dosage form while maintaining their individual pharmacokinetic optimization and achieving synergistic glycemic control.
2Speed
If immediate-release formulations are used for both metformin and DPP-4 inhibitor, then both agents achieve rapid therapeutic effect, but adverse gastrointestinal effects and potential drug interactions increase
Solution Approach 1:
The pharmaceutical composition is segmented into two distinct functional layers: a controlled-release metformin core that provides sustained release over time, and an immediate-release DPP-4 inhibitor coating that provides rapid onset. This segmentation allows each agent to be released at its optimal rate, reducing peak concentration-related side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The composition implements periodic action through its dual release profile: the immediate-release DPP-4 inhibitor provides an initial rapid therapeutic effect, followed by the controlled-release metformin that maintains steady drug levels over an extended period. This staggered release pattern optimizes glycemic control while minimizing adverse effects associated with simultaneous high concentrations of both agents.
3Object-generated harmful factors
If controlled-release formulation is used for metformin only, then gastrointestinal side effects are reduced, but the DPP-4 inhibitor does not achieve optimal rapid therapeutic effect
Solution Approach 1:
The pharmaceutical composition applies local quality by assigning different release characteristics to different spatial locations within the dosage form. The DPP-4 inhibitor in the outer coating layer provides immediate release for rapid onset, while the metformin in the inner core provides controlled release to minimize gastrointestinal irritation. Each agent's release profile is locally optimized for its specific therapeutic requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form achieves concurrent and complementary antidiabetic effects, reducing adverse interactions and improving glycemic control with optimized pharmacokinetic parameters.
Implementation Method 1
a controlled release oral dosage form comprising a core portion with metformin or its salt and an outer portion with a DPP-4 inhibitor, encapsulated by a controlled membrane film with passageways for controlled release in the gastrointestinal tract
Data Source
AI summary
An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.